Skip to main content
. Author manuscript; available in PMC: 2022 Nov 4.
Published in final edited form as: Mol Cancer Res. 2022 Aug 5;20(8):1208–1221. doi: 10.1158/1541-7786.MCR-21-0888

Figure 1. Immunohistochemical staining of MUC16 and MUC16-Cter in human pancreatic cancer primary tumor, liver metastasis samples, and patient-derived PDAC organoids.

Figure 1

A) Analysis of MUC16 expression profiles from the GEO database (GSE71729) in human PDAC primary tumor (n=145) liver metastasis (n = 25) and lung metastasis (n = 7). Data are mean ± SD. B) Immunohistochemically stained MUC16 and MUC16-Cter expression in human PDAC primary Whipple tumor tissues. C) Immunohistochemically stained MUC16 and MUC16-Cter expression in human PC liver-metastasis and lung-metastasis tissue microarrays (TMAs). D, E). The bar graph demonstrates the H-score of immunostaining of MUC16 and MUC16-Cter (scale bar, 100 μm). F, G) Immunofluorescence staining of CK19 (red) marker of ductal adenocarcinomas and MUC16 (green) and MUC16-Cter (green) in human PDAC derived organoid (n = 8) and normal tissues (n = 5) (scale bar, 20 μm).